WGS
GeneDx Holdings Corp.
$47.31
-0.02
(-0.04%)
Mkt Cap
1.40B
Volume
1,081,000
52W Range
32.21-170.87
Sector
Healthcare
Beta
2.07
EPS (TTM)
-2.66
P/E Ratio
-166.38
Revenue (TTM)
442.68M
Rev Growth (5Y)
+19.0%
EPS Growth (5Y)
N/A
Company Description
GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 427.54M | 305.45M | 202.57M | 234.69M | 212.19M | 179.32M | 196.17M |
| Net Income | (21.02M) | (52.29M) | (175.77M) | (548.98M) | (245.39M) | (241.34M) | (29.70M) |
| EPS | -0.73 | -1.94 | -7.23 | -53.63 | -74.93 | -33.16 | -4.26 |
| Free Cash Flow | 14.26M | (33.99M) | (185.86M) | (333.48M) | (211.22M) | (125.10M) | (34.18M) |
| FCF / Share | 0.53 | -1.26 | -7.64 | -32.58 | -64.49 | -22.23 | -6.08 |
| Operating CF | 33.28M | (28.50M) | (180.15M) | (319.15M) | (190.43M) | (93.13M) | (18.73M) |
| Total Assets | 570.19M | 419.38M | 418.76M | 545.26M | 554.09M | 251.64M | N/A |
| Total Debt | 151.95M | 116.17M | 119.77M | 77.13M | 32.85M | 43.26M | N/A |
| Cash & Equiv | 105.00M | 85.21M | 99.68M | 137.40M | 400.57M | 108.13M | N/A |
| Book Value | 308.18M | 245.25M | 228.02M | 253.71M | 388.10M | 4.39M | N/A |
| Return on Equity | -0.07 | -0.21 | -0.77 | -2.16 | -0.63 | -55.00 | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 102.25M | 120.99M | 116.74M | 102.69M | 87.11M | 95.64M | 76.87M | 70.51M | 62.42M | 57.42M | 53.30M | 48.71M |
| Net Income | (63.32M) | (17.67M) | (7.63M) | 10.81M | (6.53M) | 5.44M | (8.31M) | (29.17M) | (20.24M) | (25.77M) | (42.29M) | (46.72M) |
| EPS | -2.16 | -0.61 | -0.27 | 0.38 | -0.23 | 0.20 | -0.31 | -1.10 | -0.78 | -0.99 | -1.64 | -1.84 |
| Free Cash Flow | (38.86M) | (7.44M) | 9.60M | 8.05M | 4.05M | (6.23M) | (5.04M) | (5.86M) | (16.86M) | (32.23M) | (41.09M) | (56.26M) |
| FCF / Share | -1.32 | -0.28 | 0.33 | 0.28 | 0.14 | -0.23 | -0.19 | -0.22 | -0.65 | -1.24 | -1.59 | -2.21 |
| Operating CF | (32.41M) | (3.09M) | 15.77M | 10.42M | 10.18M | (3.18M) | (4.39M) | (4.50M) | (16.41M) | (29.86M) | (40.98M) | (53.50M) |
| Total Assets | 506.30M | 570.19M | 493.90M | 463.86M | 446.43M | 419.38M | 408.84M | 389.10M | 394.53M | 418.76M | 417.29M | 476.39M |
| Total Debt | 168.19M | 151.95M | 113.16M | 114.39M | 114.84M | 116.17M | 116.10M | 116.96M | 123.21M | 119.77M | 73.62M | 75.34M |
| Cash & Equiv | 93.92M | 105.00M | 95.97M | 74.12M | 99.70M | 85.21M | 57.89M | 56.08M | 83.67M | 99.68M | 87.39M | 156.66M |
| Book Value | 254.12M | 308.18M | 292.26M | 277.13M | 257.40M | 245.25M | 204.50M | 194.04M | 207.22M | 228.02M | 254.26M | 296.11M |
| Return on Equity | -0.25 | -0.06 | -0.03 | 0.04 | -0.03 | 0.02 | -0.04 | -0.15 | -0.10 | -0.11 | -0.17 | -0.16 |
WGS News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS
Is GeneDx Stock a Buys After a Company Director Purchased Over 350,000 Shares?
Barrack, Rodos & Bacine Investigates GeneDx Holdings Corp. (NASDAQ: WGS) For Possible Securities Fraud
Barrack, Rodos & Bacine Investigates GeneDx Holdings Corp. (NASDAQ: WGS) For Possible Securities Fraud
GeneDx Holdings Corp. (WGS) Securities Fraud Investigation - Levi & Korsinsky
Bragar Eagel & Squire, P.C. is Investigating GeneDx Holdings Corp. (NASDAQ:WGS) on Behalf of GeneDx Stockholders and Encourages Investors with Losses to Contact the Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS
WGS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
WGS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Fraud Investigation Opened: Levi & Korsinsky Investigates GeneDx Holdings Corp. (WGS) on Behalf of Shareholders